In green tea, epigallocatechin-3-gallate (EGCG) is thought to be the main therapeutic agent in NAFLD; EGCG decreases hepatic inflammation through reduction of cycloosxygenase-2, prostaglandin 2, NF-kB, and toll-like receptor 4 [27,28,29,30]. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.